Outcomes of ceftriaxone use compared to standard of therapy in methicillin susceptible staphylococcal aureus (MSSA) bloodstream infections

International Journal of Clinical Pharmacy

Volumn 36, Issue 6, 2014, Pages 1282-1289

  Patel, Ursula C ^a   McKissic, Erin L ^a   Kasper, Douglas ^a   Lentino, Joseph R ^a   Pachucki, Constance T ^a   Lee, Todd ^a   Lopansri, Bert K ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Bacteremia; Ceftriaxone; MSSA; S. aureus; United States; Veterans

Indexed keywords

CEFAZOLIN; CEFTRIAXONE; NAFCILLIN; VANCOMYCIN; ANTIINFECTIVE AGENT; METICILLIN;

ADULT; AGED; AMBULATORY CARE; ANTIBIOTIC THERAPY; ARTICLE; BLOODSTREAM INFECTION; CATHETER INFECTION; CATHETER REMOVAL; CENTRAL VENOUS CATHETER; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DEVICE INFECTION; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG USE; ENDOCARDITIS; EPIDURAL ABSCESS; FEMALE; FOLLOW UP; GALLBLADDER DISEASE; GALLBLADDER SLUDGE; HEALTH CARE QUALITY; HEMODIALYSIS; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; INFECTIOUS ARTHRITIS; INTERSTITIAL NEPHRITIS; LENGTH OF STAY; LIP DISEASE; LIP SWELLING; MAJOR CLINICAL STUDY; MALE; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; ORTHOPEDIC EQUIPMENT; OSTEOMYELITIS; OUTCOME ASSESSMENT; OUTPATIENT CARE; RETROSPECTIVE STUDY; SECONDARY INFECTION; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS INFECTION; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; BACTEREMIA; MIDDLE AGED; STAPHYLOCOCCAL INFECTIONS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; CEFTRIAXONE; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METHICILLIN; MIDDLE AGED; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME;

EID: 84919916552     PISSN: 22107703     EISSN: 22107711     Source Type: Journal    
DOI: 10.1007/s11096-014-9999-5     Document Type: Article

References (19)

1. Styers D, Sheehan DJ, Hogan P, Sahm DF. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann Clin Microbiol Antimicrob. 2006;5:2.
2. Naber C. Staphylococcus aureus bacteremia: epidemiology, pathophysiology, and management strategies. Clin Infect Dis. 2009;48(4):S231–6.
3. Fowler VG Jr, Miro JM, Hoen B, Cabell CH, Abrutyn E, Rubinstein E, et al. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA. 2005;293:3012–21.
4. Fowler VG Jr, Olsen MK, Corey GR, Woods CW, Cabell CH, Reller LB, et al. Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med. 2003;163:2066–72.
5. de Kraker ME, Davey PG, Grundmann H. Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in Europe. PLoS Med. 2011;8:e1001104.
6. Rubin RJ, Harrington CA, Poon A, Dietrich K, Greene JA, Moiduddin A. The economic impact of Staphylococcus aureus infection in New York City hospitals. Emerg Infect Dis. 1999;5(1):9–17.
7. Fowler VG, Sexton DJ. Treatment of Staphylococcus aureus bacteremia in adults. In: Post TW, editor. UpToDate. Waltham: UpToDate; 2010 (Accessed Oct 2010).
8. Fowler VG Jr, Sanders LL, Sexton DJ, Kong L, Marr KA, Gopal AK, et al. Outcomes of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Clin Infect Dis. 1998;27:478–86.
9. Chang FY, Peacock JE Jr, Musher DM, Triplett P, MacDonald BB, Mylotte JM, et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore). 2003;82(5):333–9.
10. Stryjewski ME, Szczech LA, Benjamin DK Jr, Inrig JK, Kanafani ZA, Engemann JJ, et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis. 2007;44:190–6.
11. Williams DN, Rehm SJ, Tice AD, Bradley JS, Kind AC, Craig WA. Practice guidelines for community-based parenteral anti-infective therapy: IDSA practice guidelines committee. Clin Infect Dis. 1997;25:787–801.
12. Paladino JA, Poretz D. Outpatient parenteral antimicrobial therapy today. Clin Infect Dis. 2010;51(2):S198–208.
13. Tice A, Siebold G, Martinelli L. Adverse effects from intravenous antibiotics with OPAT. Presented at the 40th annual meeting of the infectious diseases society of America, Chicago, IL. 2002.
14. Hamilton RA, Kowalsky SF, McCormick EM, Echols RM. Protein binding of CTX, cefoperazone, and ceftizoxime. Clin Pharm. 1987;6:567–9.
15. Schmidt S, Rock K, Sahre M, Burkhardt O, Brunner M, Lobmeyer M, et al. Effect of protein binding on the pharmacological activity of highly bound antibiotics. Antimicrob Agents Chemother. 2008;3994–4000.
16. Van der Auwera P, Klastersky J. Study of the influence of protein binding on serum bactericidal titers and killing rates in volunteers receiving ceftazidime, cefotaxime and CTX. J Hosp Infect. 1990;15:23–4.
17. Guglielmo BJ, Luber AD, Paletta D Jr, Jacobs RA. Ceftriaxone therapy for staphylococcal osteomyelitis: a review. Clin Infect Dis. 2000;30:205–7.
18. Wynn M, Dalovisio JR, Tice AD, Jiang X. Evaluation of the efficacy and safety of outpatient parenteral antimicrobial therapy for infections with methicillin-sensitive Staphylococcus aureus. South Med J. 2005;98(6):590–5.
19. Paul M, Zemer-Weisezug N, Talker O, Lishtzinsky Y, Lev B, Samra Z, et al. Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia? Clin Microbiol Infect. 2011;17(10):1581–6.